Sacituzumab govitecan for Breast Cancer User Reviews

Brand names: Trodelvy

Rating: 7.4

Sacituzumab govitecan has an average rating of 7.4 out of 10 from a total of 5 reviews for the treatment of breast cancer. 80% of reviewers reported a positive experience, while 20% reported a negative experience.

10		20%
9		20%
8		40%
7		0%
6		0%
5		0%
4		0%
3		0%
2		20%
1		0%

Ibc...
Taken for less than 1 month
January 26, 2025

"Excellent response in my daughter’s breathing. She has stage 4 inflammatory breast cancer that has spread to her lungs. After just 24 hours of taking this chemotherapy, she is breathing without difficulty."

10 / 10

Was this helpful?Yes No

0 Report

Ell...
February 5, 2024

Trodelvy (sacituzumab govitecan) "Other than neutropenia and alopecia, my side effects are minimal. I'm in the middle of my treatment plan, still hopeful that this will give me a sustained remission."

8 / 10

Was this helpful?Yes No

3 Report

Jan...
Taken for 1 to 6 months
January 19, 2024

Trodelvy (sacituzumab govitecan) "I occasionally have slurred speech and difficulty swallowing. It's kind of intermittent. No other side effect except complete alopecia"

8 / 10

Was this helpful?Yes No

3 Report

sil...
Taken for 6 months to 1 year
December 5, 2024

Trodelvy (sacituzumab govitecan) "It helped to have good PET scans and to shrink tumors in my chest."

9 / 10

Was this helpful?Yes No

1 Report

Sta...
Taken for 1 to 6 months
April 24, 2024

Trodelvy (sacituzumab govitecan) "Horrible paralyzing bone pain. Horrible constipation or diarrhea. Horrible experience. Also, face numbness."

2 / 10

Was this helpful?Yes No

1 Report

Are you taking this medicine?

Your review helps others make informed decisions.

Write a review

Reviews may be edited to correct grammar/spelling or remove inappropriate content. Reviews appearing to come from parties with a vested interest are not published. This information is not intended to endorse any medication and should not replace the expertise and judgment of healthcare professionals.